Meeting
2022 ASCO Annual Meeting
Perioperative ramucirumab in combination with FLOT versus FLOT alone for resectable esophagogastric adenocarcinoma (RAMSES/FLOT7) with high rate of signet cell component: Final results of the multicenter, randomized phase II/III trial of the German AIO and Italian GOIM.
Authors
Thorsten Oliver Goetze
Krankenhaus Nordwest, University Cancer Center Frankfurt and Institut für Klinische Krebsforschung IKF am Krankenhaus Nordwest, Frankfurt Am Main, Germany
Thorsten Oliver Goetze , Ralf-Dieter Hofheinz , Harald Schmalenberg , Dirk Strumberg , Eray Goekkurt , Stefan Angermeier , Thomas Zander , Jochem Potenberg , Hans-Georg Kopp , Daniel Pink , Gabriele Margareta Siegler , Michael Schenk , Ferdinando De Vita , Evaristo Maiello , Timo Gaiser , Disorn Sookthai , Tanita Brulin , Claudia Pauligk , Nils Homann , Salah-Eddin Al-Batran
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer
Clinical Trial Registration Number
NCT02661971
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 4042)
DOI
10.1200/JCO.2022.40.16_suppl.4042
Abstract #
4042
Poster Bd #
30
Abstract Disclosures
Similar Posters
First Author: Salah-Eddin Al-Batran
Poster
2014 ASCO Annual Meeting
HER-FLOT: Trastuzumab in combination with FLOT as perioperative treatment for patients with HER2-positive locally advanced esophagogastric adenocarcinoma: A phase II trial of the AIO Gastric Cancer Study Group.
First Author: Ralf Hofheinz
Poster
2021 ASCO Annual Meeting
Phase II study of perioperative toripalimab in combination with FLOT in patients with locally advanced resectable gastric/gastroesophageal junction (GEJ) adenocarcinoma.
First Author: Hongli Li
Poster
2021 Gastrointestinal Cancers Symposium
Phase II study of sintilimab combined with FLOT regimen for neoadjuvant treatment of gastric or gastroesophageal junction (GEJ) adenocarcinoma.
First Author: Ning Li